Motif Bio (MTFB) Savannah Petroleum (SAVP) Emmerson (EML) and Chris Bailey on (KGF) (RNK) (WG.)

Justin Waite
Daily Podcast
04:28, 17th August 2018

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast:


Graham Lumsden, CEO of Motif Bio (MTFB) explains the significance of FDA Acceptance of New Drug Application with Priority Review for their lead product, Iclaprim.

Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for hospitalised patients and designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim.

(Interview starts at 2 minute 3 seconds)

To receive news about Motif Bio (MTFB) add them to your watchlist here FOLLOW


Savannah Petroleum (SAVP) FOLLOW

Andrew Knott, CEO of Savannah Petroleum (SAVP) talks about their fourth consecutive oil discovery and progress at the company.

Savannah Petroleum's flagship assets are the R1/R2 and R3/R4 PSCs, which cover c.50% of the highly prospective Agadem Rift Basin of South East Niger, acquired in 2014/15. Savannah Petroleum are also in process of acquiring interests in the cash flow generative Uquo and Stubb Creek oil and gas fields and a 20% interest in the Accugas midstream business in South East Nigeria (the “Seven Assets”).

(Interview starts at 7 minutes 38 seconds)

To receive news about Savannah Petroleum (SAVP) add them to your watchlist here FOLLOW


Emmerson (EML) FOLLOW

Phil Cleggett, Head of Corporate Development for Emmerson (EML) talks about how their exploration target has demonstrated large-scale potash potential at their Khemisset Project.

Emmerson Plc, the Moroccan focused potash development company, is pleased to announce it has defined a significant JORC-compliant Exploration Target* at its 100% owned Khemisset Potash Project in Northern Morocco ("Khemisset" or "the Project"). The Exploration Target, covering an area of approximately 87km2 that sits within the recently granted Research Permit area, ranges from 264-616 million tonnes and at the upper end of the scale is more than double the current JORC (2012) Inferred Mineral Resource of 311.4 million tonnes 10.2% K2O and indicates the significant upside within the Project area.

(Interview starts at 16 minute 35 seconds)

To receive news about Emmerson (EML) add them to your watchlist here FOLLOW


Chris Bailey

Chris Bailey founder of Financial Orbit covers:

Kingfisher Group #KGF FOLLOW

Rank Group #RNK FOLLOW

John Wood #WG. FOLLOW

(Interview starts at 22 minute 32 seconds)


Click here to see the Top 5 Most Followed companies on Vox Markets

Click here to see the Top 5 Most Popular RNS on Vox Markets

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles